Genetic predisposition of the metabolic syndrome in healthy postmenopausal women and interaction with hormone therapy

Doctoral Dissertation uoadl:1305894 491 Read counter

Τομέας Υγείας - Μητέρας - Παιδιού
Library of the School of Health Sciences
Deposit date:
Παπαδημητρίου Δήμητρα
Dissertation committee:
Λαμπρινουδάκη Ειρήνη
Original Title:
Γενετική προδιάθεση μεταβολικού συνδρόμου σε υγιείς μετεμμηνοπαυσιακές γυναίκες και αλληλεπίδραση με την ορμονική θεραπεία
Translated title:
Genetic predisposition of the metabolic syndrome in healthy postmenopausal women and interaction with hormone therapy
Postmenopausal women have an increased prevalence of the metabolic syndrome and
this is attributed to a complex interaction between environmental and genetic
factors. The aim of the present study which enrolled 160 postmenopausal women
was to investigate the impact of methylenetetrahydrofolate reductase (ΜΤΗFR)
C677T polymorphism and plasminogen activator inhibitor - 1 polymorphism (PAI-1)
4G/5G on the components of the metabolic syndrome and other metabolic indices
in postmenopausal women under hormone therapy (HT). In the subgroup of
postmenopausal women under per os HT the TT genotype associated with an
increase in total cholesterol, LDL cholesterol and glucose, while the 4G/4G
genotype associated with increased systolic blood pressure, lipoprotein (a) and
insulin levels. Postmenopausal women with the 4G allele who received
transdermal HT had decreased triglycerides and increased HDL cholesterol and
apolipoprotein B compared to the other genotypes. In the tibolone subgroup the
same allele led to a greater decrease of HDL and apolipoprotein A and to a
relatively smaller increase of the diastolic blood pressure. Finally, in the
raloxifene subgroup the T allele associated with a greater increase of
apolipoprotein A and insulin. In the same subgroup the 4G allele correlated
with a relatively smaller increase of glycosylated haemoglobin, decreased
diastolic blood pressure and increased waist to hip ratio. The MTHFR C677T and
PAI-1 4G/5G polymorphisms modified the impact of postmenopausal hormone therapy
on the metabolic syndrome components and other metabolic indices.
Metabolic syndrome, Menopause, Methylenetrahydrofolate polymorphism MTHFR C677T, Plasminogen activator inhibitor polymorphism PAI-1 4G/5G, Hormone therapy
Number of index pages:
Contains images:
Number of references:
Number of pages:
document.pdf (2 MB) Open in new window